Circulating cell free DNA (ccfDNA) fragmentomics for early detection of colorectal carcinoma: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...

Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor–Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial Our findings revealed a ...

Michael Junkin, PhD, leads the instrumentation for Elegen’s DNA synthesis platform. He has more than 15 years of experience in the field of microfluidics, having developed systems to study ...

Liver transplant is a lifesaving surgery, but a significant number of patients experience organ rejection or other complications. A study by scientists at Georgetown University and MedStar Health has ...

Galit Meshulam-Simon is the associate director of Commercial Applications at Elegen. COVID-19 brought messenger RNA (mRNA) into the global spotlight, demonstrating its speed, flexibility, and efficacy ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the U.S. Patent and Trademark Office has issued Natera a new ...

Stanford Medicine researchers have developed a blood test capable of detecting cancers, the ways cancer resists treatments and tissue injury caused by non-cancerous conditions.

By cleverly combining new techniques for analysing DNA at the level of individual molecules, we can achieve real breakthroughs in research into ...